Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Stake Boosted by Pallas Capital Advisors LLC

Pallas Capital Advisors LLC increased its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 61.8% during the 3rd quarter, HoldingsChannel reports. The firm owned 3,321 shares of the biopharmaceutical company’s stock after acquiring an additional 1,269 shares during the period. Pallas Capital Advisors LLC’s holdings in Alnylam Pharmaceuticals were worth $975,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Capital Research Global Investors grew its position in shares of Alnylam Pharmaceuticals by 7.3% during the first quarter. Capital Research Global Investors now owns 3,144,987 shares of the biopharmaceutical company’s stock worth $470,018,000 after acquiring an additional 214,908 shares during the last quarter. Price T Rowe Associates Inc. MD grew its position in Alnylam Pharmaceuticals by 5.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,685,753 shares of the biopharmaceutical company’s stock worth $550,837,000 after purchasing an additional 201,784 shares during the last quarter. AQR Capital Management LLC increased its stake in shares of Alnylam Pharmaceuticals by 92.5% in the second quarter. AQR Capital Management LLC now owns 271,619 shares of the biopharmaceutical company’s stock valued at $65,862,000 after purchasing an additional 130,482 shares during the period. Jacobs Levy Equity Management Inc. acquired a new stake in shares of Alnylam Pharmaceuticals in the first quarter valued at approximately $18,886,000. Finally, Deerfield Management Company L.P. Series C bought a new stake in shares of Alnylam Pharmaceuticals during the second quarter valued at approximately $29,111,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

Insider Activity

In related news, CEO Yvonne Greenstreet sold 15,148 shares of the firm’s stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $270.00, for a total value of $4,089,960.00. Following the completion of the transaction, the chief executive officer now owns 73,441 shares of the company’s stock, valued at approximately $19,829,070. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, CEO Yvonne Greenstreet sold 15,148 shares of the stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $270.00, for a total value of $4,089,960.00. Following the completion of the sale, the chief executive officer now directly owns 73,441 shares of the company’s stock, valued at approximately $19,829,070. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Dennis A. Ausiello sold 20,250 shares of Alnylam Pharmaceuticals stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $262.00, for a total value of $5,305,500.00. Following the transaction, the director now directly owns 136 shares in the company, valued at approximately $35,632. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 50,398 shares of company stock worth $13,595,460 over the last 90 days. 1.50% of the stock is owned by company insiders.

Alnylam Pharmaceuticals Stock Down 0.8 %

Shares of NASDAQ ALNY opened at $284.69 on Wednesday. Alnylam Pharmaceuticals, Inc. has a 12 month low of $141.98 and a 12 month high of $304.39. The company has a market cap of $36.01 billion, a price-to-earnings ratio of -106.23 and a beta of 0.39. The business has a fifty day simple moving average of $274.75 and a 200-day simple moving average of $224.30.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.74) by $0.61. The company had revenue of $659.83 million for the quarter, compared to analyst estimates of $447.22 million. During the same quarter in the previous year, the firm posted ($2.21) EPS. Alnylam Pharmaceuticals’s quarterly revenue was up 107.0% on a year-over-year basis. As a group, sell-side analysts expect that Alnylam Pharmaceuticals, Inc. will post -2.73 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently commented on ALNY. HC Wainwright restated a “buy” rating and issued a $400.00 target price on shares of Alnylam Pharmaceuticals in a research report on Friday, October 18th. TD Cowen increased their price target on Alnylam Pharmaceuticals from $282.00 to $371.00 and gave the stock a “buy” rating in a research note on Monday, October 21st. Bank of America lifted their price objective on shares of Alnylam Pharmaceuticals from $307.00 to $314.00 and gave the company a “buy” rating in a research note on Monday, October 14th. Morgan Stanley increased their target price on shares of Alnylam Pharmaceuticals from $250.00 to $255.00 and gave the company an “equal weight” rating in a research report on Friday, July 12th. Finally, Needham & Company LLC restated a “buy” rating and set a $320.00 price target on shares of Alnylam Pharmaceuticals in a research report on Thursday, October 10th. Six investment analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the stock. Based on data from MarketBeat.com, Alnylam Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $290.86.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.